248 related articles for article (PubMed ID: 31345234)
21. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.
Cabrera CM; Jiménez P; Cabrera T; Esparza C; Ruiz-Cabello F; Garrido F
Tissue Antigens; 2003 Mar; 61(3):211-9. PubMed ID: 12694570
[TBL] [Abstract][Full Text] [Related]
22. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.
Lev A; Novak H; Segal D; Reiter Y
J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113
[TBL] [Abstract][Full Text] [Related]
23. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.
D'Urso CM; Wang ZG; Cao Y; Tatake R; Zeff RA; Ferrone S
J Clin Invest; 1991 Jan; 87(1):284-92. PubMed ID: 1898655
[TBL] [Abstract][Full Text] [Related]
24. The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution.
Ballhausen A; Przybilla MJ; Jendrusch M; Haupt S; Pfaffendorf E; Seidler F; Witt J; Hernandez Sanchez A; Urban K; Draxlbauer M; Krausert S; Ahadova A; Kalteis MS; Pfuderer PL; Heid D; Stichel D; Gebert J; Bonsack M; Schott S; Bläker H; Seppälä T; Mecklin JP; Ten Broeke S; Nielsen M; Heuveline V; Krzykalla J; Benner A; Riemer AB; von Knebel Doeberitz M; Kloor M
Nat Commun; 2020 Sep; 11(1):4740. PubMed ID: 32958755
[TBL] [Abstract][Full Text] [Related]
25. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
26. Stability and Expression Levels of HLA-C on the Cell Membrane Modulate HIV-1 Infectivity.
Parolini F; Biswas P; Serena M; Sironi F; Muraro V; Guizzardi E; Cazzoletti L; Scupoli MT; Gibellini D; Ugolotti E; Biassoni R; Beretta A; Malnati M; Romanelli MG; Zipeto D
J Virol; 2018 Jan; 92(1):. PubMed ID: 29070683
[TBL] [Abstract][Full Text] [Related]
27. Rapid cloning of HLA class I cDNAs by locus specific PCR.
Johnson DR; Biedermann BC; Mook-Kanamori B
J Immunol Methods; 2000 Jan; 233(1-2):119-29. PubMed ID: 10648862
[TBL] [Abstract][Full Text] [Related]
28. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
29. Twenty-six new polymorphic microsatellite markers around the HLA-B, -C and -E loci in the human MHC class I region.
Tamiya G; Ota M; Katsuyama Y; Shiina T; Oka A; Makino S; Kimura M; Inoko H
Tissue Antigens; 1998 Apr; 51(4 Pt 1):337-46. PubMed ID: 9583805
[TBL] [Abstract][Full Text] [Related]
30. Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer.
Echterdiek F; Janikovits J; Staffa L; Müller M; Lahrmann B; Frühschütz M; Hartog B; Nelius N; Benner A; Tariverdian M; von Knebel Doeberitz M; Grabe N; Kloor M
Oncoimmunology; 2016 Feb; 5(2):e1075692. PubMed ID: 27057447
[TBL] [Abstract][Full Text] [Related]
31. Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes.
Cheuk E; D'Souza C; Hu N; Liu Y; Lang H; Chamberlain JW
J Immunol; 2002 Nov; 169(10):5571-80. PubMed ID: 12421934
[TBL] [Abstract][Full Text] [Related]
32. Immunogenic peptide discovery in cancer genomes.
Snyder A; Chan TA
Curr Opin Genet Dev; 2015 Feb; 30():7-16. PubMed ID: 25588790
[TBL] [Abstract][Full Text] [Related]
33. [Induction of specific CD8(+) T cells against hepatocellular carcinoma-associated neoantigens].
Wang YM; Zhao BH; Chen K; Li ZJ; Qu CF
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):429-434. PubMed ID: 31216828
[No Abstract] [Full Text] [Related]
34. Human T cell receptor-mediated recognition of HLA-E.
García P; Llano M; de Heredia AB; Willberg CB; Caparrós E; Aparicio P; Braud VM; López-Botet M
Eur J Immunol; 2002 Apr; 32(4):936-44. PubMed ID: 11920559
[TBL] [Abstract][Full Text] [Related]
35. Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis.
Weichold FF; Mueller S; Kortsik C; Hitzler WE; Wulf MJ; Hone DM; Sadoff JC; Maeurer MJ
Genes Immun; 2007 Jun; 8(4):334-43. PubMed ID: 17429413
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma.
Yeon Yeon S; Jung SH; Jo YS; Choi EJ; Kim MS; Chung YJ; Lee SH
Pathol Res Pract; 2019 Jan; 215(1):209-214. PubMed ID: 30503610
[TBL] [Abstract][Full Text] [Related]
37. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
38. HLA class I polymorphism: structure and function and still questions.
Kostyu DD; Hannick LI; Traweek JL; Ghanayem M; Heilpern D; Dawson DV
Hum Immunol; 1997 Sep; 57(1):1-18. PubMed ID: 9438190
[TBL] [Abstract][Full Text] [Related]
39. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.
Paschen A; Méndez RM; Jimenez P; Sucker A; Ruiz-Cabello F; Song M; Garrido F; Schadendorf D
Int J Cancer; 2003 Mar; 103(6):759-67. PubMed ID: 12516095
[TBL] [Abstract][Full Text] [Related]
40. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
